Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan

Miho MurakamiOsaka Rheumatology Clinic, Osaka, Japan; ;Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan;

Takeshi JohkohDepartment of Radiology, Kansai Rosai Hospital, Hyogo, Japan;

Seiji HayashiNational Hospital Organization Kinki Chuo Chest Medical Center, Osaka, Japan;

Shiro OhshimaDepartment of Rheumatology and Allergology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan;

Masao MizukiDepartment of Chemotherapy, Osaka University Hospital, Osaka, Japan;

Shin-ichi NakatsukaDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan;

Minako TomobeChugai Pharmaceutical Co., Ltd., Tokyo, Japan; and Safety Evaluation Committee of tocilizumab for Castleman disease

Kazuyuki KuroyanagiChugai Pharmaceutical Co., Ltd., Tokyo, Japan; and Safety Evaluation Committee of tocilizumab for Castleman disease

Ayako NakasoneChugai Pharmaceutical Co., Ltd., Tokyo, Japan; and Safety Evaluation Committee of tocilizumab for Castleman disease

Norihiro NishimotoOsaka Rheumatology Clinic, Osaka, Japan; ;Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan; Correspondence[email protected]

show all

Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan

Supplemental Material

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan

Supplemental Material

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date